Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors von Borad, Mitesh J., Schram, Alison M., Kim, Richard D., Kamath, Suneel Deepak, Sahai, Vaibhav, Dotan, Efrat, Kelley, Robin Kate, Ponz-Sarvise, Mariano, Oh, Do-Youn, Yachnin, Jeffrey, Florou, Vaia, Cassier, Philippe Alexandre, Park, Joon Oh, Liao, Chih-Yi, Millward, Michael, Ramirez, Florence (Tianhui), Ricard, Fabien Jean, Hollebecque, Antoine, Subbiah, Vivek, Goyal, Lipika

Volltext

Abstract IA006: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study von Schram, Alison M, Subbiah, Vivek, Liao, Chih-Yi (Andy), Moreno, Victor, Desamparados, Roda, Ponz-Sarvise, Mariano, Dotan, Efrat, Cassier, Philippe Alexandre, Moreno, Irene, Varkaris, Andreas, Kim, Richard D, Garralda, Elena, Opdam, Frans, Tai, David, Italiano, Antoine, Oh, Do-Youn, Goyal, Lipika, Fontana, Elisa, Liu, Jia, Boukovala, Myrto, Ghiringelli, Francois, Borad, Mitesh J, Babiker, Hani, Jin, Zhaohui, Millward, Michael, Yachnin, Jeffrey, Kamath, Suneel Deepak, Coward, Jermaine M., Yoo, Changhoon, Kelley, Robin Kate, Sahai, Vaibhav, Bridgewater, John, Springfield, Christoph, Florou, Vaia, El-Khoueiry, Anthony, Eskens, Ferry, Lin, Bruce, Paulson, Scott, Curigliano, Giuseppe, Murphy, Meredith, Deary, Alicia, Ricard, Fabien, Yu Jen, Kai, Ramirez, Florence (Tianhui), Blakesley, Rick E., Schmidt-Kittler, Oleg, Mar, Brenton G., Park, Joon Oh, Hollebecque, Antoine

Volltext